menu
    • menu
    [{"orgOrder":0,"company":"GeneVentiv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GENV HEM","moa":"Factor Va","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GeneVentiv Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GeneVentiv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneVentiv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneVentiv Therapeutics","sponsor":"University of North Carolina","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"GENV HEM","moa":"Factor Va","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GeneVentiv Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GeneVentiv Therapeutics \/ GeneVentiv Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"GeneVentiv Therapeutics \/ GeneVentiv Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by GeneVentiv Therapeutics

    Menu

    GeneVentiv Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GeneVentiv Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            GeneVentiv Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GENV HEM

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the Treatment of Hemophilia A or B With or ...

                            Details : GENV-HEM is an Adeno-Associated Virus first gene therapy treatment in development to treat both hemophilia A or B with or without inhibitors.

                            Product Name : GENV HEM

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : GENV HEM

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GeneVentiv Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            GeneVentiv Therapeutics

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GENV HEM

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Recipient : University of North Carolina

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia

                            Details : GeneVentiv plans to move the therapy into the clinic mid-2022. The technology, designated as GENV HEM offers a cure for all types of hemophilia patients with or without inhibitors to their missing clotting factors.

                            Product Name : GENV HEM

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 11, 2020

                            Lead Product(s) : GENV HEM

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Recipient : University of North Carolina

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth